IP Library Granted Patent US 11,884,975
Granted Patent B2
US 11,884,975 · App. 17/193,279 · Granted Jan 30, 2024

Sequencing methods and compositions for prenatal diagnoses

Inventors: Richard P. Rava (Redwood City, CA); Manjula Chinnappa (Foster City, CA); David A. Comstock (Sunnyvale, CA); Gabrielle Heilek (Mountain View, CA); Brian Kent Rhees (Chandler, AZ)
Assignee: VERINATA HEALTH, INC.
C12Q1/6869C12Q1/6806C12Q1/6809G16B20/10G16B30/10G16H10/40C12Q1/6883C12Q2600/106C12Q2600/112
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,884,975
App. No.
17/193,279
Granted
Jan 30, 2024
Kind
B2
Abstract

The invention provides methods for determining aneuploidy and/or fetal fraction in maternal samples comprising fetal and maternal cfDNA by massively parallel sequencing. The method comprises a novel protocol for preparing sequencing libraries that unexpectedly improves the quality of library DNA while expediting the process of analysis of samples for prenatal diagnoses.

Claims (12)

1. A method for preparing a sequencing library from a test sample comprising nucleic acid molecules, wherein said nucleic acids molecules are human cell-free DNA (cfDNA) molecules, wherein the method comprises the consecutive steps of end-repairing, dA-tailing and adaptor ligating said nucleic acids molecules, wherein said consecutive steps exclude purifying the end-repaired products prior to the dA-tailing step and exclude purifying the dA-tailing products prior to the adaptor-ligating step, and wherein said consecutive steps are performed in less than 1 hour.

2. The method of claim 1 , wherein said consecutive steps are performed in the absence of polyethylene glycol.

3. The method of claim 1 , wherein said nucleic acids molecules are not subjected to fragmentation prior to the consecutive steps of end-repairing, dA-tailing and adaptor ligating said nucleic acids molecules.

4. The method of claim 1 further comprising sequencing said sequencing library.

5. The method of claim 4 , wherein said sequencing is a next generation sequencing (NGS).

6. The method of claim 4 , wherein said sequencing is massively parallel sequencing.

7. The method of claim 4 , wherein said sequencing comprises an amplification.

8. The method of claim 4 , wherein said sequencing is single molecule sequencing.

9. The method of claim 1 , wherein the sample is a plasma sample derived from peripheral blood that comprises a mixture of cfDNA derived from normal and cancerous cells.

10. The method of claim 6 , wherein:

(i) said sequencing is massively parallel sequencing using sequencing-by-synthesis with reversible dye terminators; or

(ii) said sequencing is massively parallel sequencing using sequencing-by-ligation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2021
From: RAVA, RICHARD P.; COMSTOCK, DAVID A.; CHINNAPPA, MANJULA; HEILEK, GABRIELLE; RHEES, BRIAN K.
To: ARTEMIS HEALTH, INC.
Reel/Frame 058264/0115 →
CHANGE OF NAME Recorded Nov 29, 2021
From: ARTEMIS HEALTH, INC.
To: VERINATA HEALTH, INC.
Reel/Frame 058264/0137 →
Continuity (7)
Continuation 15601951 · May 22, 2017
Continuation 12958353 · Dec 1, 2010
Provisional Application 61455849 · Oct 26, 2010
Provisional Application 61407017 · Oct 26, 2010
Provisional Application 61360837 · Jul 1, 2010
Provisional Application 61296358 · Jan 19, 2010
Related Publication 20210340613A1 · Nov 4, 2021
Cited By (1)
US 12,522,869